A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer (NRG-GY018)

Project: Clinical Trial

Project Details

StatusActive
Effective start/end date11/22/19 → …